Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...

I t’s vaccination season, which for most people means getting immunized for flu and COVID-19 (and RSV for infants, pregnant ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

COVID is still circulating but Canadians' intentions to get a booster dose of a COVID-19 vaccine have decreased dramatically since 2021 You can save this article by registering for free here. Or ...

The biotech company, which makes the Spikevax RNA-based Covid-19 vaccine, reported net income of $13 million, or 3 cents a share, compared with a loss of $3.6 billion, or $9.53 a share, in the same ...

On November 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial ...

They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in mice and hamsters.

A British doctor who was disgruntled about his inheritance and injected his mother's boyfriend with poison presented as a ...

Moderna Chief Human Resources Officer Tracey Franklin has expanded her role to Chief People and Digital Technology Officer, overseeing the Company's talent and digital functions. Brad Miller, Chief ...

New research from Emory University reveals that nasal autoantibodies in COVID-19 patients may help predict disease severity, ...